Brought to you by 
Valeant pays $8.7bn for Bausch & Lomb
07 Aug 2013
Executive Summary
Valeant Pharmaceuticals International Inc. is paying $8.7bn in cash to acquire private eye health company Bausch & Lomb Inc.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- OTC, Consumer
-
Medical Devices
- Diagnostic Imaging Equipment & Supplies
- Implantable Devices
- Laser
- Surgical Equipment & Devices
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Valeant pays $8.7bn for Bausch & Lomb
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice